Molecure Files an Investigational New Drug (IND) Application for Lead Clinical Candidate OATD-01 with U.S. FDA Ahead of a Planned Phase 2 Pulmonary Sarcoidosis Study

Molecure, a clinical stage biotechnology company, has filed an Investigational New Drug (IND) application with the U.S. FDA for OATD-01, a first-in-class Chitotriosidase (CHIT1) inhibitor that could become the new standard of care for sarcoidosis. The IND will allow Molecure to initiate a global Phase 2 study to evaluate OATD-01's safety and efficacy in approximately 90 patients with active pulm..